HMy2.CIR Cells

Unit

5 x 10^6 cells/ml

Cell Type

Immortalized Cells

Tissue Type

B lymphoblast cell lines

Organism

Human

Donor History
Growth Properties

Suspension

Growth Conditions

Culture medium: IMDM

,

w: 4.5 g/L Glucose

,

w: 4 mM L-Glutamine

,

w: 25 mM HEPES

,

w: 1.0 mM Sodium pyruvate

,

w: 3.024 g/L NaHCO3 (Cytion article number 820800a). Supplements: Supplement the medium with 10% FBS. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/HMy2.CIR-Cells/305126

SKU: 305126 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

The HMy2.CIR cell line was developed through gamma irradiation and subsequent selection for the loss of HLA class I antigen expression from the HMy.2 B lymphoblastoid cell line. This parental cell line is a fast-growing mutant derived from the ARH-77 cell line. HMy2.CIR cells are particularly valuable as hosts for transfected class I major histocompatibility antigen genes, offering a versatile platform for studying antigen presentation and immune response mechanisms.
The ARH-77 cell line, from which HMy2.CIR is ultimately derived, is known to be positive for Epstein-Barr nuclear antigen (EBNA+) and Epstein-Barr viral capsid antigen (EBVCA+). Consequently, the HMy2.CIR cell line is also presumed to be EBNA positive. This cell line is characterized by its expression of small amounts of HLA Cw4, but it does not express HLA A or B locus products. This unique antigen expression profile makes HMy2.CIR cells a useful model for immunological research, particularly in the study of HLA class I-restricted antigen processing and presentation.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.